ascopubs.org

Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with ...

A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. Background: OSI-906 is a potent inhibitor of IGF-1R and IR tyrosine kinase ...
Nature

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be ...
TechRepublic

Comparative Study of OSI & TCP/IP Reference Model

A reference model is a virtual model which defines how communication should take place. It logically divides the processes which are required for the communication into layers. This concept is known ...
MarketWatch

OSI, Genetech: Tarceva study shows survival improvement

SAN FRANCISCO (MarketWatch) -- OSI Pharmaceuticals Inc. and Genentech Inc. said after Wednesday's closing bell that results from a Phase III study show Tarceva improved survival in patients with ...
ascopubs.org

Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in ...

A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. Background: OSI-906 is ...